Clostridium difficile and inflammatory bowel disease: Role in pathogenesis and implications in treatment

Orna Nitzan, Mazen Elias, Bibiana Chazan, Raul Raz, Walid Saliba

Abstract

Clostridium difficile (C. difficile) is the leading cause of antibiotic associated colitis and nosocomial diarrhea. Patients with inflammatory bowel disease (IBD) are at increased risk of developing C. difficile infection (CDI), have worse outcomes of CDI-including higher rates of colectomy and death, and experience higher rates of recurrence. However, it is still not clear whether C. difficile is a cause of IBD or a consequence of the inflammatory state in the intestinal environment. The burden of CDI has increased dramatically over the past decade, with severe outbreaks described in many countries, which have been attributed to a new and more virulent strain. A parallel rise in the incidence of CDI has been noted in patients with IBD. IBD patients with CDI tend to be younger, have less prior antibiotic exposure, and most cases of CDI in these patients represent outpatient acquired infections. The clinical presentation of CDI in these patients can be unique-including diversion colitis, enteritis and pouchitis, and typical findings on colonoscopy are often absent. Due to the high prevalence of CDI in patients hospitalized with an IBD exacerbation, and the prognostic implications of CDI in these patients, it is recommended to test all IBD patients hospitalized with a disease flare for C. difficile. Treatment includes general measures such as supportive care and infection control measures. Antibiotic therapy with either oral metronidazole, vancomycin, or the novel antibiotic-fidaxomicin, should be initiated as soon as possible. Fecal macrobiota transplantation constitutes another optional treatment for severe/recurrent CDI. The aim of this paper is to review recent data on CDI in IBD: role in pathogenesis, diagnostic methods, optional treatments, and outcomes of these patients.
cells from more than 1000 different bacterial species\cite{1,2} that play an important role in conservation of mucosal innate and adaptive immune function, integrity of the epithelial barrier and nutrient absorption\cite{3-6}. Disruption of the gut microbiota (dysbiosis) has been linked with many gastrointestinal conditions\cite{7,8}. Accumulating evidence suggests that inflammatory bowel disease (IBD) results from an inappropriate inflammatory response to intestinal microbes in a genetically susceptible host\cite{9-11}. Dysbiosis in IBD may also contribute to disease severity, and is correlated with the occurrence of abscesses in patients with Crohn's disease (CD) and need for surgery at a younger age\cite{2,3,12}.

*Clostridium difficile* (*C. difficile*) is an anaerobic gram-positive, spore-forming, toxin-producing bacillus that causes intestinal disease varying from a mild diarrhea illness to severe colitis\cite{13-16}. The burden of *C. difficile* infection (CDI) has increased dramatically over the past decade and it is now recognized that *C. difficile* is responsible for 20%-30% of cases of antibiotic associated diarrhea and 50%-75% of cases of antibiotic associated colitis\cite{17,18}. *C. difficile* is also the leading cause of nosocomial diarrhea, with incidence ranging from 1:100-1:1000 hospitalized patients\cite{19,20}. Loss of intestinal microbial equilibrium, most commonly following antibiotic use, creates an environment susceptible to colonization of *C. difficile* and subsequent CDI\cite{21,22}.

IBD has been found to be associated with *C. difficile*\cite{23-26}. Patients with IBD are at increased risk of developing CDI, have worse outcomes of CDI-including higher rates of colectomy and death, and experience higher rates of recurrence\cite{27-30}. However, it is still not clear whether *C. difficile* is a cause of IBD or a consequence of the inflammatory state in the intestinal environment. The association between IBD and *C. difficile* may be due to different factors, such as drugs that are used for the treatment of IBD that might alter the intestinal flora and promote colonization (including repeat courses of antibiotics), altered immune and nutritional status, frequent hospitalizations, and even genetic predisposition\cite{31,32}.

In this review we will try to focus on the role of *C. difficile* in IBD pathogenesis, the unique aspects of *C. difficile* infections in patients with IBD, and the implications for testing and treatment.

### The role of *C. difficile* in IBD

The initial trigger responsible for the onset of IBD is not yet known. A complex interplay between the immune system, environmental factors, such as stress and diet, enteric infections, and genetic factors play a role in the pathogenesis of IBD\cite{33,34}. Gut microbiota interacts with both the innate and adaptive immune systems, playing a pivotal role in maintenance and disruption of gut immune quiescence\cite{35}. Different bacteria have been implicated in the pathogenesis of IBD, including *Mycobacterium avium paratuberculosis*, enterotoxicogenic *Bacteroides fragilis*, adherent/invasive *Escherichia coli*, *Campylobacter jejuni*, *Listeria monocytogenes*, *Chlamydia sp.*, *Aeromonas hydrophila*, *Salmonella typhi*, and *C. difficile*\cite{35,36}. However, to date there is no conclusive evidence that a specific pathogen is responsible for IBD onset or relapse.

*C. difficile* has been found to be associated with IBD. Different studies found that patients with IBD, including ulcerative colitis (UC) and CD, are at increased risk of developing CDI. A study based on a large cohort of IBD patients in the United States found that CDI was more common in UC patients (2.8%) as compared to the general inpatient population (0.4%), and another study reported an adjusted odds ratios for CDI in all IBD, CD, and UC admissions from 1998-2004 to be 2.9, 4.0, and 2.1 respectively\cite{37,38}. Since 2003 there has been a dramatic rise in the incidence of CDI with severe outbreaks described in Canada, United States and England, which have been attributed to a new and more virulent strain designated BI/NAP1/027, that has also been found in patients with IBD\cite{39,40,41}. A parallel rise in the incidence of CDI in patients with IBD has also been noted. During 1998-2004 CDI rates approximately doubled in CD (9.5 to 22.3/1000 admissions) and tripled in UC (18.4 to 57.6/1000)\cite{42}. A retrospective observational study found that the rate of CDI in IBD patients increased from 1.8% in 2004 to 4.6% in 2005, with the majority of patients having colonic IBD\cite{43}. More recent studies, found that 5.5%-19% of patients with an IBD exacerbation, tested positive for *C. difficile* infection, and as many as 3.5% of children hospitalized due to IBD, were diagnosed with CDI\cite{44,45}. Furthermore, analysis of a registry database suggests that 10% of IBD patients will develop a *C. difficile* infection at some point, and approximately 10% of CDI occur at the time of IBD diagnosis\cite{46}. Patients with IBD also have higher rates of asymptomatic carriage of *C. difficile* 8.2% (9.4% in patients with UC and 6.9% in patients with CD), versus 1% in healthy volunteers\cite{47}. It is possible, though, that the seemingly increased risk of CDI in patients with IBD is due to increased surveillance of this population for CDI. There are studies that question the role of CDI in IBD. A recent prospective Dutch study found a low prevalence of *C. difficile* in IBD patients and did not find any association of *C. difficile* with disease activity, disease subtype (CD or UC), gender, antibiotic, and immunosuppressive therapy\cite{48}.

Though it is still not clear if *C. difficile* causes IBD, it is understood that *C. difficile* can cause an infectious colitis superimposed on IBD, or may precipitate an IBD flare leading to simultaneous inflammatory processes, and it is nowadays considered a risk factor for IBD exacerbation. The association between *C. difficile* and IBD is mediated by a chain of events, including recurrent hospitalizations, that are a known risk factor for acquisition of *C. difficile* and CDI, medications administered to patients with IBD (including immunomodulatory and antimicrobial agents) that disturb the intestinal flora, thus allowing for *C. difficile* colonization and adherence, and a decreased nutritional status that promotes *C. difficile* infection\cite{31,32}. Thus, *C. difficile* can colonize the intestines of these patients and produce its two potent exotoxins: toxin A (“enterotoxin”) and toxin B (“cytotoxin”) that bind to receptors on intestinal epithelial cells. This activates a cascade of proinflam-
risk factors for CDI in patients with IBD are similar to those in the general population, such as- older age, medications (antibiotic/immunosuppressive agents), hospitalization, residence at a long term facility and comorbidities. However, there are a few differences in risk factors for CDI in patients with IBD. IBD patients with CDI tend to be younger, and 76% of C. difficile infections in these patients represent outpatient acquired infections, as opposed to patients without IBD were the most part of C. difficile infections are hospital acquired. IBD has been found to be a risk factor for outpatient acquired CDI. In a study done in our medical center, on 115 patients with CDI, we found a trend towards a higher rate of CDI in community acquired CDI versus hospital acquired CDI (20.2% vs 9.7%, unpublished data).

Also, up to 40% of IBD patients do not have documented antibiotic exposure prior to presentation with CDI. Patients with IBD receive various types of immunosuppressive drugs that might predispose to CDI, and steroid treatment has been found to increase the risk of CDI 3 fold in these patients, though other immunomodulatory drugs such as purine analogs, methotrexate and biological agents, have not been consistently found to increase the risk of CDI. Combination treatment with different immunomodulatory agents can increase the risk of CDI as was found in pediatric patients receiving concomitant therapy of methotrexate and anti-TNF-α, where 28% of patients developed CDI.

Clinical characteristics

Patients with IBD can have different and unique clinical presentations of CDI. To begin with, the similarity in symptoms between CDI and a flare of IBD (diarrhea, abdominal pain, fever and leukocytosis) make it extremely difficult to distinguish between the two. C. difficile in IBD may also show atypical features such as frequent bloody stools, as opposed to watery stools in patients without IBD. Diarrhea may even be absent in postoperative patients who receive narcotics for pain control and develop paralytic ileus. In IBD patients with ileostomies, C. difficile can cause acute enteritis, which can manifest as an increase in ileostomy output, nausea, fever and leukocytosis. In patients who have undergone ileal pouch anal anastomosis as treatment for IBD, C. difficile infection might be a triggering factor for pouchitis, which presents as an increase of the number of stools per day, with or without constitutional symptoms such as weight loss. In one study, 10.7% of patients with ileal pouch anal anastomosis, presenting with pouchitis, were found to have CDI. Another study demonstrated that 18.3% of pouchitis were positive for C. difficile toxin. In patients with men 3.5 times more likely than women to develop C. difficile pouchitis.

Typical findings of CDI on colonoscopy (such as pseudomembranous exudates, which are found in up to 60% of patients with CDI) are often absent in patients with IBD (0%-13% of cases). This might be due to a weakened inflammatory response in the colonic epithelial

Table 1: Unique features and clinical implications of Clostridium difficile infection in patients with inflammatory bowel disease

| Risk factors | CDI IN PATIENTS WITH IBD |
|-------------|-------------------------|
| Colonic IBD | The unique features and clinical implications of CDI in patients with IBD are summarized in Table 1. |
| Immunomodulatory drugs | Risk factors |
| In comparison to patients with no IBD: younger age, more community acquired cases, less prior antibiotic exposure | As noted above, patients with IBD are at increased risk for CDI, but this risk varies among different subsets of these patients. One of the major risk factors for CDI in patients with IBD is colonic IBD, either UC or CD with colitis-with 91% of patients with IBD suffering from CDI, reported to have colonic IBD, and a higher incidence of CDI was found in patients with left sided and extensive disease as compared to distal disease. Other |
| Clinical characteristics | 8 |
| Diarrhea (can be bloody), often mimics a flare of IBD | 8 |
| In patients with ileostomies: acute enteritis (an increase in ileostomy output, nausea, fever and leukocytosis) | 8 |
| In patients with ileal pouch anal anastomosis: pouchitis | 8 |
| Often no pseudomembranes on colonoscopy | 8 |
| Outcomes and complications | 8 |
| Higher rates of toxic megacolon and colonic perforation | 8 |
| Higher rates of colectomies | 8 |
| Longer length of hospital stay | 8 |
| Increased mortality | 8 |
| Diagnosis: | 8 |
| Test for CDI in all IBD patients hospitalized with a disease flare | 8 |
| As in patients with no IBD-one step molecular assays or two step algorithms: screening with EIA for GDH, followed by EIA for toxins and/or a molecular assay | 8 |
| Treatment: | 8 |
| 1 Escalation of immunosuppression should be avoided during CDI | 8 |
| 2 Antibiotics treatment as in non IBD patients | 8 |
| Mild to moderate disease: oral metronidazole | 8 |
| Severe disease: oral vancomycin + intravenous metronidazole | 8 |
| Fidaxomicin-less recurrences (no data in IBD patients) | 8 |
| Severe disease: oral vancomycin + intravenous metronidazole | 8 |
| 3 Fecal macrobiota transplantation | 8 |
| Limited data in IBD patients though seems to be effective | 8 |

IBD: Inflammatory bowel disease; CDI: Clostridium difficile infection.
environment in patients with chronic active IBD or due to immunosuppressive drugs that hamper the development of pseudomembranes, which are caused by disruption of cellular cytoskeleton by toxins, ulcer formation and leakage of serum proteins, inflammatory cells and mucus.

Outcomes

C. difficile infections have a different and often more severe clinical course in patients with IBD. These patients have higher rates of endoscopies, higher rates of complications such as toxic megacolon and colonic perforation, higher rates of colectomies, longer length of hospital stay, and increased mortality\[29,30\]. Different studies found high rates of colectomies in these patients, ranging from 20% to 45%\[30,32\], with one study finding a 6 fold increase in bowel surgery in patients with CDI with and without IBD\[30\]. Patients with IBD also experience more recurrences of CDI, than patients without IBD\[29\]. Mortality is also increased in these patients with one study demonstrating a 6%-18% case fatality rate in patients with IBD and CDI vs 1.4%-2.1% fatality rate in patients with CDI alone\[40\]. A large study of the inpatient care database in the United States found that hospitalized patients with concurrent CDI and IBD had a 4 times higher mortality rate than those admitted for IBD or CDI alone\[63\].

All of these special aspects of CDI in patients with IBD should cause physicians to be alert to the possibility of CDI in a patient with an IBD exacerbation and prompt rapid diagnosis and treatment.

Diagnosis

CDI is a clinical diagnosis supported by laboratory findings. As mentioned before, it is often difficult to distinguish between CDI and an exacerbation of IBD, because of the similarity in symptoms, and moreover, IBD patients may have a different clinical presentation of CDI. Laboratory findings in both CDI and IBD are also similar, including: leukocytosis, hypoalbuminemia, and fecal leukocytosis\[38\]. Endoscopic findings that are typical for CDI, such as colonic pseudomembranes, are also lacking in most patients with IBD that present with CDI\[38\]. As noted above, patients with IBD and CDI often acquire the infection in the outpatient setting and in many there is no previous documented antibiotic exposure\[29,33\].

Due to the high prevalence of CDI in patients hospitalized with an IBD exacerbation, the suspected causal association between CDI and flare of IBD, and the prognostic implications of CDI in these patients, it is recommended by the American college of gastroenterology CDI Guidelines Task Force, to test all IBD patients hospitalized with a disease flare for C. difficile\[28\]. Also, the European Crohn’s and Colitis Organization guidelines recommend testing for Clostridium difficile infection in patients with severe or refractory UC\[65\]. Patients should be tested even in the absence of traditional risk factors such as antibiotic exposure.

There are various laboratory tests used in the diagnosis of CDI. Only loose, watery, or semi-formed stool should be tested for C. difficile and specimens should be kept at 4 °C if delay in testing is anticipated due to degradation of C. difficile toxin at room temperature\[66,67\]. The different tests that have been used to date are\[68-73\]: (1) Selective aerobic culture: the most sensitive diagnostic method, cannot distinguish toxin-producing strains from non-toxin producing strains, time and labor consuming and thus reserved for epidemiologic studies\[73\]; (2) Cell culture cytotoxicity neutralization assay: detects the presence of toxin B in stool by its cytopathic effects in a cell or tissue culture, is time consuming, with a sensitivity of 65%-90%, and is rarely performed today\[73\]; (3) enzyme immunoassay (EIA) for C. difficile toxins A and B: sensitivity for toxins A and B is 60%-75% and specificity is higher (up to 99%)\[74,75\]. Was the routine diagnostic assay for CDI in most microbiology laboratories in recent years, but due to its low sensitivity, is not recommended today as the initial diagnostic assay\[75\]; (4) EIA for C. difficile glutamate dehydrogenase (GDH), an enzyme produced in all C. difficile strains: sensitivity of 75% > 90%, but cannot differentiate between toxin positive and toxin negative strains\[74\]; and (5) Polymerase chain reaction (PCR): detect toxin A and B genes, are highly sensitive and specific\[75,76\], and provide rapid results (within as little as 1 h).

Current recommendation for CDI diagnosis implement either one step molecular assays or two step algorithms with screening with EIA for GDH, followed by EIA for toxins and/or a molecular assay\[67,68\]. In patients with IBD, there is no evidence to date, that testing for CDI should be done differently. A recent retrospective study that compared the frequency and clinical outcomes of IBD inpatients with CDI, found that a greater percentage of patients tested positive by PCR for toxin B as compared with ELISA for toxins A + B, but the clinical outcomes were the same, regardless of method of testing\[75\]. More research is needed to determine the optimal diagnostic test for CDI in patients with IBD. Due to high rates of asymptomatic colonization of C. difficile in patients with IBD, only patients with significant diarrhea should be tested for CDI.

Treatment

Treatment of CDI includes general measures such as supportive care with attention to correction of fluid losses and electrolyte imbalances, cessation of the inciting antibiotic as soon as possible (if possible), implementation of infection control policies-including hand hygiene with soap and water which is more effective than alcohol-based hand sanitizers in eradication of C. difficile spores\[67,70\]. Antimotility agents such as loperamide and opiates have traditionally been avoided in CDI for fear of decreasing toxin clearance and increasing the risk of ileus and/or megacolon, but the evidence that they cause harm is equivocal\[70\].

Specific antibiotic therapy should be started as soon as possible, and empiric therapy is indicated pending results of diagnostic testing if the clinical suspicion is high and
when severe or complicated CDI is suspected. Currently, there are several drugs in use for treatment of CDI including: metronidazole (oral or intravenous), vancomycin (oral or per rectum), oral rifaximin, and a newer drug-oral fidaxomicin. A Cochrane systematic review from 2011 found no statistically significant difference in efficacy between vancomycin and other antibiotics including metronidazole, fusidic acid, nitoxazoline or rifaximin[86]. The updated guidelines for the treatment of CDI released by the Infectious Diseases Society of America and the Society for Healthcare epidemiology of America suggest that the initial choice of treatment should be determined based on the severity of illness and depending if it is a first episode of CDI or a recurrence[80]. There are different scoring systems to assess the severity of illness, including the severity score index that consists of 9 criteria, each accounting for one point: altered mental status, white blood cell count > 20000 or < 1500, albumin < 2.5 mg/dL, ascites or colitis by imaging, mean arterial pressure < 65 mmHg, fever > 38.3 °C, tachycardia > 110 bpm and admission to intensive care unit. 1-3 points indicate mild disease, 4-6 points moderate disease, and ≥ 7 points severe disease[69]. For an initial episode of mild to moderate CDI-metronidazole, at a dose of 500 mg orally 3 times per day for 10-14 d, is considered the drug of choice. Vancomycin at a dose of 125 mg orally 4 times per day for 10-14 d is the drug of choice for an initial episode of severe CDI. Vancomycin, administered 500 mg orally 4 times per day (and 500 mg in approximately 100 mL normal saline per rectum every 6 h as a retention enema, if ileus is present) with or without intravenously administered metronidazole 500 mg intravenously every 8 h, is the regimen of choice for the treatment of severe, complicated CDI. Treatment of the first recurrence of CDI is usually with the same regimen as for the initial episode but should be stratified by disease severity. Treatment of the second or later recurrence of CDI is with vancomycin therapy using a tapered and/or pulse regimen[86].

Recent studies of fidaxomicin, 200 mg orally twice daily, compared with oral vancomycin, demonstrated non inferiority of clinical response after 10 d of treatment and superior sustained responses with a decrease in recurrences (13% vs 24% with vancomycin treatment)[82]. Among patients who received concomitant antibiotics, treatment with fidaxomicin resulted in higher cure rates (90% vs 79.4%) and lower recurrence rates (16.9% vs 29.2% with vancomycin)[83]. Due to these and other findings, fidaxomicin might be a promising treatment for patients with risk factors known to portend relapse and severe infection[86], though two different economical analyses reported conflicting results of the cost effectiveness of using fidaxomicin as first-line treatment for CDI[84,85].

In patients with IBD and CDI, there are no guidelines or evidence from prospective studies to suggest that one antibiotic regimen is better than another. Failure rates of up to 50% have been reported in IBD patients treated with metronidazole[86]. Considering the worse outcomes of patients with IBD and CDI, some institutions use vancomycin as first-line treatment in these patients. In a single center study, where vancomycin was adopted as first-line therapy in IBD patients with CDI, colectomy rates decreased from 45.5% to 25% within 1 year after the change of policy[88]. There are no data as of yet regarding the use of fidaxomicin in the IBD patient population, though in another group of immune suppressed patients-recipients of solid organ and hematopoietic stem cell transplantation, fidaxomicin achieved over all cure rates in 86% of episodes and recurrence rate was 7%[89].

Concomitant use of immunomodulators is another unresolved issue in patients with IBD and CDI. A retrospective multicenter European study comparing hospitalized IBD patients with CDI treated with antibiotics and immunomodulators or antibiotics alone, found that the primary outcome of complications including colectomy or death within 3 mo occurred in 12% of patients treated with both, as compared to none of the patients treated with antibiotics alone[80]. The use of 2 or more immunomodulators further increased the risk of complications. In a survey of North American gastroenterologists, there was significant disagreement on whether combination antibiotics and immunomodulators or antibiotics alone should be given in patients with an IBD flare and CDI[91]. The American College of Gastroenterology CDI task force, has given a conditional recommendation, with low quality supporting evidence, that ongoing immunosuppression can be maintained in patients with CDI, although escalation of immunosuppression should be avoided[86].

Fecal macrobiota transplantation (FMT) through retention enemas, rectal tube, colonoscopy, nasogastric and nasoduodenal tubes, or upper endoscopy is another option for treating recurrent CDI through restoration of a healthy microbiome in the lower gastrointestinal tract. Different studies have reported success rates of FMT approaching 90% in patients with recurrent CDI[92,93]. A randomized prospective trial, found that duodenal infusion of donor feces following vancomycin treatment was significantly more effective for the treatment of recurrent CDI than the use of vancomycin alone[94]. Data on the use of FMT among IBD patients is limited, though a recent systematic review found that out of 12 patients with IBD and CDI treated with FMT, all became toxin negative, with symptomatic resolution in 11 out of 12 patients[95]. A recent review of FMT[96] notes that though there are no guidelines concerning FMT for treatment of CDI in patients with IBD, after FMT and eradication of C.difficile, the severity of IBD is gradually reduced with improved responses to medications for IBD. FMT is considered a safe treatment, though a recent paper reported a case of a flare of UC in a patient who received FMT for CDI[97].

In patients after restorative proctocolectomy and ileal pouch anal anastomosis that present with C. difficile pouchitis, treatment is empirical because there are no published prospective trials. Studies suggest that metronidazole is not completely protective against CDI of
the pouch, as this infection has developed in patients on metronidazole therapy, thus in these patients vancomycin might be considered as first line therapy[9].

CONCLUSION

Patients with IBD are at increased risk of developing CDI and having worse outcomes, including higher rates of colectomy and death. There has also been a rise in the percentage of patients with IBD that suffer from CDI during recent years, even in those lacking classic risk factors for CDI. Patients with IBD often present with unique and more severe symptoms of CDI. Diagnosis of CDI in patients with IBD warrants a high index of suspicion and physicians should be alert to the possibility of CDI in any patient with an IBD exacerbation. All hospitalized patients with a flare of IBD should be tested for CDI and antibiotic treatment should be initiated rapidly, especially in severe cases, where vancomycin is the treatment of choice. More studies are needed to better understand the pathogenetic role of CDI in IBD exacerbations, to define what are the best diagnostic methods for CDI in these patients, to assess the efficacy of newer treatments such as fidaxomicin in patients with CDI and IBD, and to better address the question of concurrent treatment with immunomodulatory agents.

REFERENCES

1. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, Relman DA. Diversity of the human intestinal microbial flora. Science 2005; 308: 1635-1638 [PMID: 15831718 DOI: 10.1126/science.110591]
2. Savage DC. Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol 1977; 31: 107-133 [PMID: 334036 DOI: 10.1146/annurev.mi.31.030177.000543]
3. Zoetendal EG, Rajilic-Stojanovic M, de Vos WM. High-throughput diversity and functionality analysis of the gastrointestinal tract microbiota. Gut 2008; 57: 1605-1615 [PMID: 18941009 DOI: 10.1136/gut.2007.136063]
4. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JL. The human microbiome project. Nature 2007; 449: 804-810 [PMID: 17943116 DOI: 10.1038/nature06244]
5. Bäckhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JL. Host-bacterial mutualism in the human intestine. Science 2005; 307: 1915-1920 [PMID: 15790844 DOI: 10.1126/science.1104527]
6. Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 2005; 122: 107-118 [PMID: 16009137 DOI: 10.1016/j.cell.2005.05.007]
7. Porchiarini F, Tortora A, Gabrielli M, Bertucci F, Gigante G, Ianiro G, Ojetti V, Scarpellini E, Gasharrini A. The role of intestinal microbiota and the immune system. Eur Rev Med Pharmacol Sci 2013; 17: 323-333 [PMID: 23426335]
8. Robles Alonso V, Guamer F. Linking the gut microbiota to human health. Br J Nutr 2013; 109 Suppl 2: S21-S26 [PMID: 23368877 DOI: 10.1017/S0007114512005235]
9. Tamboli CP, Neat C, Desreumaux P, Colombel JF. Dysbiosis in inflammatory bowel disease. Gut 2004; 53: 1-4 [PMID: 14684564 DOI: 10.1136/gut.53.1.1]
10. MacDonald TT, Monteleone G. Overview of role of the immune system in the pathogenesis of inflammatory bowel disease. Adv Exp Med Biol 2006; 579: 98-107 [PMID: 16620013 DOI: 10.1007/0-387-35778-4_6]
11. Dupaul-Chicoine J, Dagenais M, Saleh M. Crosseattle between the intestinal microbiota and the innate immune system in intestinal homeostasis and inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 2227-2237 [PMID: 2369404 DOI: 10.1097/MIB.0b013e31828dca7]
12. Kaakoush NO, Day AS, Huinoda KD, Leach ST, Lemberg DA, Dowd SE, Mitchell HM. Microbial dysbiosis in pediatric patients with Crohn’s disease. J Clin Microbiol 2012; 50: 3258-3266 [PMID: 22837318 DOI: 10.1128/JCM.01396-12]
13. Frank DN, St Amand AL, Feldman RA, Harnap N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 2007; 104: 13780-13785 [PMID: 17696621 DOI: 10.1073/pnas.0706625104]
14. Rubin MS, Bodenstein LE, Kent KC. Severe Clostridium difficile colitis. Dis Colon Rectum 1995; 38: 350-354 [PMID: 7720439 DOI: 10.1007/BF02054220]
15. Lamontagne F, Labbe AC, Haeck O, Lesur O, Lalancette Dagenais M, Saleh M. Crosstalk between the intestinal microbiota and the innate immune system in intestinal homeostasis and inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 2227-2237 [PMID: 2369404 DOI: 10.1097/MIB.0b013e31828dca7]
16. Kaakoush NO, Day AS, Huinoda KD, Leach ST, Lemberg DA, Dowd SE, Mitchell HM. Microbial dysbiosis in pediatric patients with Crohn’s disease. J Clin Microbiol 2012; 50: 3258-3266 [PMID: 22837318 DOI: 10.1128/JCM.01396-12]
17. Frank DN, St Amand AL, Feldman RA, Harnap N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 2007; 104: 13780-13785 [PMID: 17696621 DOI: 10.1073/pnas.0706625104]
18. Bartlett JG. Clostridium difficile: clinical considerations. Rev Infect Dis 1990; 12 Suppl 2: S243-S251 [PMID: 2406876 DOI: 10.1093/clinids/12.Supplement_2.S243]
19. Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 2006; 145: 758-764 [PMID: 17116920 DOI: 10.7326/0003-4819-145-1-200611210-00008]
20. Sohn S, Climo M, Diekema D, Fraser V, Herwaldt L, Marino S, Noskin G, Perl T, Song X, Tokars J, Warren D, Wong E, Yokoe DS, Zembower T, Sepkowitz KA. Varying rates of Clostridium difficile-associated diarrhea at prevention epicenter hospitals. Infect Control Hosp Epidemiol 2005; 26: 676-679 [PMID: 1615632 DOI: 10.1086/502601]
21. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006; 12: 409-415 [PMID: 16704777 DOI: 10.3143/676-679]
22. Kelly CP, LaMont JT. Clostridium difficile infection. Annu Rev Med 1998; 49: 375-390 [PMID: 9592970 DOI: 10.1146/annurev.med.49.1.375]
23. Thomas C, Stevenson M, Riley TV. Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. J Antimicrob Chemother 2003; 51: 1339-1350 [PMID: 12746372]
24. Bien J, Falagani V, Bozko P. The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease? Therap Adv Gastroenterol 2013; 6: 53-68 [PMID: 2332005 DOI: 10.1177/1758281X124590]
25. Sinh P, Barrett TA, Yun L. Clostridium difficile Infection and Inflammatory Bowel Disease: A Review. Gastroenterol Res Pract 2011; 2011: 136604 [PMID: 21915178 DOI: 10.1155/2011/136604]
26. Reddy SS, Brandt LJ. Clostridium difficile infection and inflammatory bowel disease. J Clin Gastroenterol 2013; 47: 666-671 [PMID: 23507767 DOI: 10.1097/MCG.0b013e3182b8298a]
27. Navaneethan U, Venkatesh PG, Shen B. Clostridium difficile infection and inflammatory bowel disease: understanding the evolving relationship. World J Gastroenterol 2010; 16: 4892-4900 [PMID: 20954275]
28. Navaneethan U, Mukewar S, Venkatesh PG, Lopez R, Shen B.
Clostridium difficile infection is associated with worse long term outcome in patients with ulcerative colitis. *J Crohns Colitis* 2012; 6: 330-336 [PMID: 22405170 DOI: 10.1016/j.jcobi.2009.08.005]

28 Jodkowski D, Young Y, Abreu MT. Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection. *Dig Dis Sci* 2010; 55: 415-420 [PMID: 19255850 DOI: 10.1007/s10620-009-0749-9]

29 Issa M, Vijayapal A, Graham MB, Beaulieu DB, Otterson MF, Lundeen S, Skaroos S, Weber LR, Komorowski RA, Knox JP, Emmons J, Bajaj JS, Binion DG. Impact of Clostridium difficile on inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2007; 5: 345-351 [PMID: 17368234]

30 Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. *Gut* 2008; 57: 205-210 [PMID: 17905821]

31 Freeman HJ. Recent developments on the role of Clostridium difficile in inflammatory bowel disease. *World J Gastroen-terol* 2008; 14: 2794-2796 [PMID: 18473400]

32 Ananthakrishnan AN, Oxford EC, Nguyen DD, Sauk J, Yajnik V, Xavier RJ. Genetic risk factors for Clostridium difficile infection in ulcerative colitis. *Aliment Pharmacol Ther* 2013; 38: 522-530 [PMID: 23848254 DOI: 10.1111/apt.12425]

33 Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. *Nature* 2007; 448: 427-434 [PMID: 17653185]

34 Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. *Nat Rev Immunol* 2008; 8: 458-466 [PMID: 18500230]

35 Packey CD, Sartor RB. Interplay of commensal and pathogenic bacteria, genetic mutations, and immunoregulatory defects in the pathogenesis of inflammatory bowel diseases. *J Intern Med* 2008; 263: 597-606 [PMID: 18479259 DOI: 10.1111/j.1365-2796.2008.01962.x]

36 Yu CG, Huang Q. Recent progress on the role of gut microbiota in the pathogenesis of inflammatory bowel disease. *J Dig Dis* 2013; 14: 513-517 [PMID: 23848393 DOI: 10.1111/1751-2980.12087]

37 Lidor M, Langevitz P, Shoenfeld Y. The role of infection in inflammatory bowel disease: initiation, exacerbation and protection. *Isr Med Assoc J* 2009; 11: 558-563 [PMID: 19966852]

38 Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser S0140-6736(78)92699-5

39 Ribeiro RA, Lima AA. Clostridium difficile toxin A induces the release of neutrophil chemotactic factors from rat peri toneal macrophages: role of interleukin-1beta, tumor necrosis factor alpha, and leukotrienes. *Infect Immun* 1997; 65: 2740-2746 [PMID: 9199444]

40 Warney M, Kelly CP. Pathogenicity of Clostridium Difficile toxins, in Microbial Pathogenesis and the Intestinal Epithelial Cell, G. Hecht, Editors. Washington (DC): American Society for Microbiology Press, 2003: 503-524

41 Pippin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hyervirulent strain in Quebec. *CMAJ* 2005; 173: 1037-1042 [PMID: 16179431 DOI: 10.1503/cmaj.050978]

42 Loo VG, Bourgault AM, Poirier L, Lamotho F, Michaud S, Turgeon N, Toye B, Beaudoin L, Frost EH, Gilsa R, Brandard P, Dendukuri N, Béliveau C, Oughton M, Brukner I, Dascal A. Host and pathogenic factors for Clostridium difficile infection and colonization. *N Engl J Med* 2011; 365: 1693-1703 [PMID: 22047560 DOI: 10.1056/NEJMoa1012413]

43 Issa M, Ananthakrishnan AN, Binion DG. Clostridium difficile and inflammatory bowel disease. *Inflamm Bowel Dis* 2008; 14: 1432-1442 [PMID: 18484669 DOI: 10.1002/ibd.20500]

44 Bossuyt P, Verhaegen J, Van Assche G, Rutgeerts P, Ver meire S. Increasing incidence of Clostridium difficile-associated diarrhea in inflammatory bowel disease. *J Crohns Colitis* 2009; 3: 4-7 [PMID: 21172241 DOI: 10.1016/j.crohns.2008.09.003]

45 Schneeweis S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. *Aliment Pharmacol Ther* 2009; 30: 253-264 [PMID: 19438424 DOI: 10.1111/j.1365-2036.2009.03975.x]

46 Kariv R, Navaneethan U, Venkatesh GP, Lopez R, Shen B. Impact of Clostridium difficile infection in patients with ulcerative colitis. *J Crohns Colitis* 2011; 5: 34-40 [PMID: 21272802 DOI: 10.1016/j.crohns.2010.09.007]

47 Absal F, Faubion WA. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn’s colitis: a case series. *Inflamm Bowel Dis* 2012; 18: 1488-1492 [PMID: 21882301 DOI: 10.1002/ibd.21885]
difficile-associated diarrhea: a growing problem. *Clin Gastroenterol Hepatol* 2007; 5: 310-311 [PMID: 17368229]

88 Issa M, Weber LR, Skaros S, Beaulieu DB, Emmons J, Knox JF, Lundeen S, Otterton MF, Binion DG. Decreasing rates of colectomy despite high rates of hospitalization in *Clostridium difficile* infected IBD patients: a tertiary referral center experience. *Gastroenterology* 2007; 132: A663 (abstract)

89 Clutter DS, Dubrovskaya Y, Merl MY, Teperman L, Press R, Saffar A. Fidaxomicin versus conventional antimicrobial therapy in 59 recipients of solid organ and hematopoietic stem cell transplantation with *Clostridium difficile*-associated diarrhea. *Antimicrob Agents Chemother* 2013; 57: 4501-4505 [PMID: 23836168 DOI: 10.1128/AAC.01120-13]

90 Ben-Horin S, Margalit M, Bossuyt P, Maul J, Shapira Y, Bojic D, Cheremsh I, Al-Rifai A, Schoepfer A, Bosani M, Allez M, Lakatos PL, Bossa F, Eser A, Stefanelli T, Carbonnel F, Katsanos K, Checchin D, Miera IS, Chowers Y, Moran GW. Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and *Clostridium difficile* infection. *Clin Gastroenterol Hepatol* 2009; 7: 981-987 [PMID: 19523534 DOI: 10.1016/j.cgh.2009.05.031]

91 Yanai H, Nguyen GC, Yun L, Lebwohl O, Navaneethan U, Stone CD, Ghazi L, Moayyedi P, Brooks J, Bernstein CN, Ben-Horin S. Practice of gastroenterologists in treating flaring inflammatory bowel disease patients with *Clostridium difficile*: antibiotics alone or combined antibiotics/immunomodulators? *Inflamm Bowel Dis* 2011; 17: 1540-1546 [PMID: 21674710 DOI: 10.1002/ibd.21514]

92 MacConnachie AA, Fox R, Kennedy DR, Seaton RA. Faecal transplant for recurrent *Clostridium difficile*-associated diarrhoea: a UK case series. *QJM* 2009; 102: 781-784 [PMID: 19726581 DOI: 10.1093/qjmed/hcp118]

93 Brandt LJ, Aroniadis OC, Mellow M, Kanatzar A, Kelly C, Park T, Stollman N, Rohlke F, Surawicz C. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent *Clostridium difficile* infection. *Am J Gastroenterol* 2012; 107: 1079-1087 [PMID: 22450732 DOI: 10.1038/ajg.2012.60]

94 van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zozentz EC, de Vos WM, Visser CE, Kuiper EJ, Barletsma NJ, Tijsen JC, Speelman P, Dijkgraaf MG, Keller JJ. Duodenal infusion of donor feces for recurrent *Clostridium difficile*. *N Engl J Med* 2013; 368: 407-415 [PMID: 23323867 DOI: 10.1056/NEJMoA1205037]

95 Anderson JL, Edney RJ, Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. *Aliment Pharmacol Ther* 2012; 36: 503-516 [PMID: 22827693 DOI: 10.1111/j.1365-2036.2012.05220.x]

96 Smits LP, Bouter KE, de Vos WM, Borody TJ, Nieuwdorp M. Therapeutic potential of fecal microbiota transplantation. *Gastroenterology* 2013; 145: 946-953 [PMID: 24018052 DOI: 10.1053/j.gastro.2013.08.058]

97 De Leon LM, Watson JB, Kelly CR. Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent *Clostridium difficile* infection. *Clin Gastroenterol Hepatol* 2013; 11: 1036-1038 [PMID: 23669309 DOI: 10.1016/j.cgh.2013.04.045]
